Issue 10/2010
Content (19 Articles)
Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy?
Stanisław Szala, Iwona Mitrus, Aleksander Sochanik
Pre-operative intracellular glutathione levels of peripheral monocytes as a biomarker to predict survival of colorectal cancer patients
Kazuko Uno, Kiyotaka Okuno, Takuma Kato, Saeko Tada-Oikawa, Norimichi Kan, Hideo Saotome, Katsumi Yagi, Junji Hamuro
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
Lee M. Krug, Tao Dao, Andrew B. Brown, Peter Maslak, William Travis, Sara Bekele, Tatyana Korontsvit, Victoria Zakhaleva, Jedd Wolchok, Jianda Yuan, Hao Li, Leslie Tyson, David A. Scheinberg
Identification and characterization of Ch806 mimotopes
Lin Yang, Hua Jiang, Bizhi Shi, Huamao Wang, Jinjun Li, Hai Wang, Ming Yao, Zonghai Li
Response definition criteria for ELISPOT assays revisited
Z. Moodie, L. Price, C. Gouttefangeas, A. Mander, S. Janetzki, M. Löwer, M. J. P. Welters, C. Ottensmeier, S. H. van der Burg, Cedrik M. Britten
The effect of radiotherapy on NKT cells in patients with advanced head and neck cancer
Kouichi Kobayashi, Yuriko Tanaka, Shigetoshi Horiguchi, Shouji Yamamoto, Nakayama Toshinori, Akira Sugimoto, Yoshitaka Okamoto
Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study
Shimon Slavin, Aliza Ackerstein, Reuven Or, Michael Y. Shapira, Benjamin Gesundheit, Nadir Askenasy, Shoshana Morecki
Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors
Jaafar Bennouna, Vincent Levy, Hélène Sicard, Hélène Senellart, Marie Audrain, Sandrine Hiret, Frédéric Rolland, Heriberto Bruzzoni-Giovanelli, Marie Rimbert, Céline Galéa, Jérome Tiollier, Fabien Calvo
A polysaccharide extracted from Grifola frondosa enhances the anti-tumor activity of bone marrow-derived dendritic cell-based immunotherapy against murine colon cancer
Yuki Masuda, Koichi Ito, Morichika Konishi, Hiroaki Nanba
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
Noriyuki Yamada, Satoshi Oizumi, Eiki Kikuchi, Naofumi Shinagawa, Jun Konishi-Sakakibara, Atsushi Ishimine, Keisuke Aoe, Kenichi Gemba, Takumi Kishimoto, Toshihiko Torigoe, Masaharu Nishimura
Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion
Stephanie L. Goff, Laura A. Johnson, Mary A. Black, Hui Xu, Zhili Zheng, Cyrille J. Cohen, Richard A. Morgan, Steven A. Rosenberg, Steven A. Feldman
CD8+ T cell recognition of polymorphic wild-type sequence p5365–73 peptides in squamous cell carcinoma of the head and neck
Pedro A. Andrade Filho, Daisuke Ito, Albert B. DeLeo, Robert L. Ferris
Ninth international conference on progress in vaccination against cancer (PIVAC 9), 8–10 October 2009, Sofia, Bulgaria
Elissaveta Naumova, Stéphanie McArdle, Graham Pawelec
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
Gerty Schreibelt, Jurjen Tel, Kwinten H. E. W. J. Sliepen, Daniel Benitez-Ribas, Carl G. Figdor, Gosse J. Adema, I. Jolanda M. de Vries
DNA vaccination strategies for anti-tumour effective gene therapy protocols
Emanuela Signori, Sandra Iurescia, Emanuela Massi, Daniela Fioretti, Pieranna Chiarella, Mariangela De Robertis, Monica Rinaldi, Giancarlo Tonon, Vito Michele Fazio
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Suzanne Ostrand-Rosenberg
The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions
Federico Garrido, Ignacio Algarra, Angel M. García-Lora
Cetuximab-dependent ADCC in cancer: dream or reality?
Alessandro Ottaiano, Stefania Scala, Vincenzo Rosario Iaffaioli
Response to the letter to the editors by Ottaiano et al.: “Cetuximab-dependent ADCC in cancer: dream or reality?”
Robert L. Ferris, Soldano Ferrone